Century Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Century Therapeutics (IPSC).

Price Target Range — 10 Quarters

Analyst Consensus — 7 Analysts

6Buy

1Hold

Consensus RatingBuy# Analysts7Avg. Consensus PT$7Upside to Avg. PT+262.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 27, 2026	Mizuho	Salim Syed	Initiate	Outperform	$8
Apr 21, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$2→$5
Jan 20, 2026	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$2→$4
Nov 17, 2025	Leerink Partners	Daina Graybosch	Downgrade	Outperform→Market Perform	$7→$2
May 16, 2025	Chardan Capital	Geulah Livshits	PT Cut	Buy	$7→$6
Apr 3, 2025	HC Wainwright & Co.	Mitchell Kapoor	PT Cut	Buy	$5→$2
Mar 28, 2025	Guggenheim	Kelsey Goodwin	Maintained	Buy	—
Mar 24, 2025	Chardan Capital	Geulah Livshits	PT Cut	Buy	$11→$7
Mar 21, 2025	Guggenheim	Kelsey Goodwin	PT Cut	Buy	$12→$5
Mar 20, 2025	Piper Sandler	Edward Tenthoff	PT Cut	Overweight	$4→$2
Jan 22, 2025	Guggenheim	Michael Schmidt	Maintained	Buy	—
Jan 22, 2025	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Buy	$5
Dec 30, 2024	Piper Sandler	Edward Tenthoff	PT Cut	Overweight	$12→$4
Nov 7, 2024	Chardan Capital	Geulah Livshits	PT Cut	Buy	$17→$11
Nov 6, 2024	HC Wainwright & Co.	Mitchell Kapoor	PT Cut	Buy	$9→$5
Aug 15, 2024	HC Wainwright & Co.	Mitchell Kapoor	PT Cut	Buy	$11→$9
Jun 17, 2024	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$9→$12
Jun 4, 2024	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Buy	$11
May 10, 2024	HC Wainwright & Co.	Mitchell Kapoor	PT Cut	Buy	$13→$11
Apr 12, 2024	Piper Sandler	Edward Tenthoff	PT Cut	Overweight	$10→$9

More with Benzinga EdgeGet Access

Analyst Ratings News

This GE Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Top Wall Street analysts changed outlook on top names. See analyst ratings page for upgrades, downgrades, and initiations. Check out what analysts think of GE stock.

Avi Kapoor

PRO
Mizuho Initiates Coverage On Century Therapeutics with Outperform Rating, Announces Price Target of $8

Mizuho analyst Salim Syed initiates coverage on Century Therapeutics (NASDAQ:IPSC) with a Outperform rating and announces Price Target of $8.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Century Therapeutics, Raises Price Target to $5

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Century Therapeutics (NASDAQ:IPSC) with a Buy and raises the price target from $2 to $5.

Benzinga Newsdesk

PRO
Leerink Partners Downgrades Century Therapeutics to Market Perform, Lowers Price Target to $2

Leerink Partners analyst Daina Graybosch downgrades Century Therapeutics (NASDAQ:IPSC) from Outperform to Market Perform and lowers the price target from $7 to $2.

Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Century Therapeutics, Lowers Price Target to $6

Chardan Capital analyst Geulah Livshits maintains Century Therapeutics (NASDAQ:IPSC) with a Buy and lowers the price target from $7 to $6.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Century Therapeutics, Lowers Price Target to $2

HC Wainwright & Co. analyst Mitchell Kapoor maintains Century Therapeutics (NASDAQ:IPSC) with a Buy and lowers the price target from $5 to $2.

Benzinga Newsdesk

Century Therapeutics Inc

Century Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This GE Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

PRO
Mizuho Initiates Coverage On Century Therapeutics with Outperform Rating, Announces Price Target of $8

PRO
HC Wainwright & Co. Maintains Buy on Century Therapeutics, Raises Price Target to $5

PRO
Leerink Partners Downgrades Century Therapeutics to Market Perform, Lowers Price Target to $2

PRO
Chardan Capital Maintains Buy on Century Therapeutics, Lowers Price Target to $6

PRO
HC Wainwright & Co. Maintains Buy on Century Therapeutics, Lowers Price Target to $2

People Also Watch

People Also Watch

Benzinga

Benzinga

Century Therapeutics Inc

Century Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This GE Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

PROMizuho Initiates Coverage On Century Therapeutics with Outperform Rating, Announces Price Target of $8

PROHC Wainwright & Co. Maintains Buy on Century Therapeutics, Raises Price Target to $5

PROLeerink Partners Downgrades Century Therapeutics to Market Perform, Lowers Price Target to $2

PROChardan Capital Maintains Buy on Century Therapeutics, Lowers Price Target to $6

PROHC Wainwright & Co. Maintains Buy on Century Therapeutics, Lowers Price Target to $2

People Also Watch

People Also Watch

PRO
Mizuho Initiates Coverage On Century Therapeutics with Outperform Rating, Announces Price Target of $8

PRO
HC Wainwright & Co. Maintains Buy on Century Therapeutics, Raises Price Target to $5

PRO
Leerink Partners Downgrades Century Therapeutics to Market Perform, Lowers Price Target to $2

PRO
Chardan Capital Maintains Buy on Century Therapeutics, Lowers Price Target to $6

PRO
HC Wainwright & Co. Maintains Buy on Century Therapeutics, Lowers Price Target to $2